Dear SHOW Delegates,

After careful consideration we are emailing you to advise that we will be postponing SHOW until 2023. With the proliferation of omicron cases and the increase in travel restrictions we feel this is the most responsible course
of action.

SHOW has been rooted in the intimate and interactive format, active audience participation and multidisciplinary panels. Our consensus is that it would be very challenging to recreate this atmosphere in a virtual or hybrid format.

We are currently working with the hotel and will announce the 2023 date shortly. We are targeting a late January or early February date.

We will be reimbursing your registration with in the next few days and the hotel will be contacting you to confirm the cancellation of your booking. PLEASE NOTE- the hotel is allowing delegates to rebook at the same discounted rate for same dates. Instructions on how to rebook your room will be included in the hotels email.

Thank you again for your commitment to SHOW. We apologize for the late change, and will look forward to seeing you at SHOW 2023.

Best regards,

Chairs, Symposium on Hepatic Oncology at Whistler (SHOW)

Associate Professor, Department of Radiology, Faculty of Medicine, University of British Columbia
Associate Professor, School of Biomedical Engineering, Faculty of Applied Sciences, University of British Columbia
Voluntary Professor, Department of Interventional Radiology, Miller School of Medicine, University of Miami
Vancouver, BC

Wendy Lam, B Sc (Pharm), MD, FRCP(C)
Director, BC Community Oncology Trialists
Burnaby Hospital Regional Cancer Centre
Burnaby, BC

Andrew Kennedy, MD, FACRO
Physician in Chief, Radiation Oncology, Sarah Cannon
Director, Radiation Oncology Research, Sarah Cannon Research Institute
Sarah Cannon Cancer Center
Nashville, TN

Head, Liver Transplant Program
Head, Hepatopancreatobiliary Surgery
Vancouver General Hospital
Clinical Associate Professor
University of British Columbia
Vancouver, BC

Learning Objectives:

  • Establish principles of liver-directed locoregional therapy in the setting of pancreatic neuroendocrine disease, hepatocellular carcinoma and metastatic colorectal carcinoma.
  • Review evidence base for systemic, surgical, ablative and embolic strategies in liver-directed therapies in HCC mCRC and pNET.
  • Provide context for locoregional therapy as it relates to the timing of systemic therapies.
  • Engage in case-based panels that exemplify the role of multidisciplinary board review.
  • Demonstrate the synergies and optimization of therapeutic options in the treatment of both primary and metastatic liver cancer.
  • Create a forum for open discussion and cross disciplinary knowledge translation.
  • Assess recent advances in systemic treatment of hepatocellular carcinoma, pancreatic neuroendocrine disease, and colorectal cancer.
  • Facilitate direct discussion and interaction with world recognized disease experts.

Target Audience

    • Physicians, nurses, allied health professionals, and trainees with a scope of practice that involves management of both primary and hepatic neoplasia. Topics and themes will focus on practical and community-based practice.